title: Prognostic significance of p53, bcl-2 and EGFR in carcinoma of the endometrium.
abstract: OBJECTIVE
  To evaluate the part played by several parameters in the prognosis of patients with endometrial carcinoma.
  
  
  METHODS
  Eighty imprint smears from fresh endometrial tumor specimens were studied immunocytochemically for the expression of p53, bcl-2 and epidermal growth factor receptor. Also, the presence of estrogen receptor (ER) and progesterone receptor (PR) in the tumor tissue was measured. The data obtained were related to survival, and associations were sought between the parameters studied.
  
  
  RESULTS
  Strong associations were found between advanced stage, high grade, lymph node metastases at diagnosis, nonendometrioid histology and p53 expression with poor survival. Bcl-2 expression was associated with good five-year survival. ER expression was associated marginally with good five-year survival, but PR expression was not. A strong association was found between p53 and advanced disease, stage and lymph node metastases at diagnosis. An association between EGFR positivity and survival was not found.
  
  
  CONCLUSIONS
  p53 Expression of uterine tumors is an independent and strong indicator of poor prognosis. Even patients with stage I and II disease at surgery who have p53-positive tumors must be considered at high risk.
authors.affiliation: Department of Cytology and Clinical Therapeutics, Alexandra Hospital, Medical School, University of Athens, Greece.
authors.forename: P
authors.initials: P
authors.lastname: Athanassiadou
authors.forename: E
authors.initials: E
authors.lastname: Petrakakou
authors.forename: A
authors.initials: A
authors.lastname: Liossi
authors.forename: L
authors.initials: L
authors.lastname: Nakopoulou
authors.forename: C
authors.initials: C
authors.lastname: Zerva
authors.forename: A
authors.initials: A
authors.lastname: Dimopoulos
authors.forename: P
authors.initials: P
authors.lastname: Athanassiades
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D016889:Endometrial Neoplasms / Q000737:chemistry* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D066246:ErbB Receptors / Q000032:analysis*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000032:analysis*; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D015996:Survival Rate; D016159:Tumor Suppressor Protein p53 / Q000032:analysis*
chemical_list: D019253:Proto-Oncogene Proteins c-bcl-2; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D016159:Tumor Suppressor Protein p53; D066246:ErbB Receptors